Background-Patients with human immunodeficiency virus (HIV) infection are at increased risk of accelerated coronary artery disease (CAD) and cardiovascular events. Stress echocardiography (SE) is routinely used for risk stratification and prognosis of patients with known or suspected CAD. The prognostic value of SE in this high-risk group is unknown. The purpose of this study was to evaluate the prognostic value of SE in HIV-infected patients with known or suspected CAD.
T he number of people living with human immunodeficiency virus (HIV) infection in the United States and worldwide continues to rise. More than 33.4 million adults and adolescents worldwide and 1.1 million (US prevalence rate, 447.8 per 100 000 population) in the United States are currently living with HIV. 1, 2 The increase in prevalence is a reflection of the steady high incidence, combined with a decreased mortality rates as the result of the beneficial effect of highly active antiretroviral therapy (HAART). However, despite this improved survival, current clinical and epidemiological studies consistently correlate HIV infection with increased risk of coronary artery disease (CAD) and adverse cardiovascular events. Histopathologic studies have shown the presence of severe and extensive CAD in HIV-infected patients, which is out of proportion for their age and cardiovascular risk factors. 3, 4 HIV-infected adults, after controlling for age and sex, have 3-times greater odds of having obstructive CAD compared with noninfected adults. 5
Clinical Perspective on p 370
Established markers of CAD, such as carotid intima-media thickness and coronary artery calcium score, are worse in patients with HIV compared with age-matched control subjects. 6, 7 Coronary computed tomographic angiography demonstrated an increased prevalence (59% versus 34%, Pϭ0.002) and degree of coronary atherosclerosis compared with non-HIV-infected patients with similar cardiovascular risk factors. 8 Individuals with HIV have 1.4-to 3-fold higher risk of cardiovascular events compared with age-matched and cardiovascular risk factor-matched control subjects. 9 -11 The mechanisms underlying the increased cardiovascular risk in these patients are related to HIV replication and may be a result of metabolic derangements caused by HAART. 12, 13 HIV infection is associated with chronic immune activation and inflammation, premature immune senescence, endothelial dysfunction, and impairment of ATP-binding cassette transporter A1-dependent cholesterol efflux from human macrophages, thus increasing atherogenesis. 14, 15 Furthermore, antiretroviral therapy has been associated with hypercholesterolemia, hypertriglyceridemia, and insulin resistance.
Hence, it is increasingly important to identify HIV-infected patients at higher risk for atherosclerosis and cardiovascular events. Stress echocardiography (SE) is an established noninvasive technique for the diagnosis, risk stratification, and prognosis of CAD. 16 -19 However, the prognostic value of SE in HIV-infected patients is not known. The objective of the present study was 2-fold: (1) to evaluate if SE can risk-stratify and prognosticate HIV infected patients and (2) to evaluate if SE has incremental prognostic value over traditional clinical variables.
Methods

Study Population
We identified 347 consecutive patients with known diagnosis of HIV infection, referred by their treating physicians for clinically indicated SE. Successful prospective follow-up was obtained in 341 (98%) patients. Patients with acute myocardial infarction (MI) (Ͻ3 days), hemodynamically significant valvular abnormalities, hemodynamic instability, poor acoustic windows (Ͻ13 of 16 segments visualized by echo), pregnancy, or inability to give informed written consent were excluded from the study (nϭ30). The final cohort consisted of 311 patients. Written informed consent was obtained from all patients, and the study was approved by the institution's review board. Clinical characteristics, including HIV-related characteristics, medications, and indications for testing, were recorded at the time of SE.
Exercise Echocardiography Protocol
Maximal exercise treadmill testing was performed with the use of standard Bruce protocol. Patients exercised to general fatigue, with premature termination for severe angina, ventricular tachycardia, hemodynamically significant arrhythmias, or hemodynamic instability. Failure to achieve 85% of maximal agepredicted heart rate was followed by conversion to a dobutamine SE study. The maximal degree of ST-segment change at 80 ms after the J point on the ECG was measured. Patients with Ն1-mm ST-segment change after stress (if no baseline ST-segment changes) or Ն2-mm ST-segment change (if baseline ST-segment changes were present) were considered to have a positive stress ECG response. Postexercise echocardiographic images were acquired within 30 to 60 seconds after termination of treadmill exercise. 16 
Dobutamine Echocardiography Protocol
Dobutamine was administered intravenously, beginning at a dose of 5 to 10 g/kg per minute and increased by 5 to 10 g/kg every 3 minutes up to a maximum of 50 g/kg per minute or until a study end point was achieved. The end points for termination of the dobutamine infusion included development of new segmental wall motion abnormalities, attainment of 85% maximum predicted heart rate, or the development of significant adverse effects related to the dobutamine infusion. Atropine was administered intravenously in 0.25-mg increments every 3 minutes up to a maximum of 2.0 mg if a study end point was not achieved at the maximum dobutamine dose. 16 ␤-Blockers were held on the morning of the test, as is the protocol in our laboratories. Before every stress test, a complete transthoracic echocardiogram was performed. During both types of SE, transthoracic echocardiographic images were obtained with the patient in the left lateral decubitus position, using commercially available ultrasound equipment. Seven standard echocardiographic views were obtained with each acquisition: parasternal long-axis, parasternal short-axis, apical 4-chamber, apical 3-chamber, apical 2-chamber, subcostal short-axis, and subcostal 4-chamber views. The acquisition sequences were as follows: For each patient, the apical 4-chamber was acquired first, followed by 3-chamber, 2-chamber, and then parasternal longand short-axis views (typically within 30 to 40 seconds). This was then followed by the subcostal views (typically within the next 5 to 10 seconds). All images were acquired within 60 seconds, and the entire sequence was repeated again to acquire a second run of images. Echocardiographic images were acquired at baseline, with each increment of dobutamine infusion, and during the recovery phase. Cardiac rhythm was monitored throughout the SE protocol, and 12-lead ECGs and blood pressure measurements were obtained at baseline, at each level of stress, and during the recovery phase.
Echocardiographic Image Analysis
The left ventricle (LV) was divided into 16 segments, as recommended by the American Society of Echocardiography, and a score assigned to each segment at baseline, with each stage of stress and during the recovery phase. 19 Each segment was scored as follows: 1, normal; 2, mild to moderate hypokinesis (reduced wall thickening and excursion); 3, severe hypokinesis (marked reduced wall thickening and excursion); 4, akinesis (no wall thickening and excursion); and 5, dyskinesis (paradoxical wall motion away from the center of the LV during systole). 16 
Abnormal SE
A normal response to stress was defined as normal wall motion at rest, with an increase in wall thickening and excursion during stress. An SE with abnormal resting wall motion, showing increase in wall thickening and excursion during stress, was also considered normal. An abnormal SE was present if at least 1 of the following was observed: (1) an abnormal resting LV wall segment that did not increase in thickness and excursion during stress (fixed wall motion abnormality); (2) deterioration of LV wall segment thickening and excursion during stress (increase in wall motion score of Ն1 grade); and/or (3) a biphasic response with dobutamine stress.
SE Wall Motion Indexes
The peak wall motion score index (WMSI) after stress was derived from the cumulative sum score of 16 LV wall segments divided by the number of visualized segments. The following indexes that reflect the extent and severity of LV wall motion abnormalities at peak stress were calculated:
(1) Maximal severity was the score of the LV wall segment(s) with the greatest value (worst wall motion grade) at peak stress (range, 1 to 5).
(2) Maximal ischemia was the largest difference in severity score of the LV wall segments from peak stress to rest.
(3) Total extent is the number of abnormal LV wall segments at peak stress (range, 0 to 16).
(4) Ischemic extent was the number of new (ischemic) wall motion abnormalities during stress that increase in wall motion score of Ͼ1 (range, 0 to 16). 17 All echocardiograms, including resting LV ejection fraction and regional LV wall motion were visually interpreted by an experienced echocardiographer who was blinded to patient demographics, treatment, and outcome.
Patient Follow-Up
Serial prospective follow-up was obtained in all patients by means of a physician-directed telephone interview, using a standardized questionnaire. If the patient died during follow-up, the closest surviving relative and the patient's physician were interviewed to determine the cause of death. The outcome of the study was a composite of nonfatal MI and cardiac death. Patients (nϭ28) who underwent revascularization during follow-up were not censored at the time of revascularization. Nonfatal MI was defined as myocardial ischemia resulting in abnormal cardiac biomarkers (Ͼ99th percentile of the upper limits of normal) in association with symptoms or ECG changes indicative of ischemia. The definition of cardiac death required documentation of significant arrhythmias, cardiac arrest, or both, or death attributable to congestive heart failure or MI in the absence of any other precipitating factors. Cardiac death was confirmed by review of the hospital medical record and/or death certificate. Autopsy records were reviewed when available (Ͻ1%). In the case of death out of hospital for which no autopsy was performed, sudden unexpected death was attributed to a cardiac cause. Subjects who died of noncardiac causes were censored at date of death. Only the first event was considered for each patient. Adjudication of cardiac death and MI were done by physicians who were blinded to the clinical, stress ECG, and echocardiographic outcome of the patients.
Statistical Analysis
All analysis was carried out with the use of a standard statistical package (SPSS for Windows, version 16.0, SPSS Inc, Chicago, IL). Continuous variables are expressed as meanϮSD or median (25th/75th percentile) and were compared by means of the 2-sample Student t test (for normally distributed variables) or the Wilcoxon rank sum test (for other variables). Categorical variables are expressed as frequencies and percentages and were compared by the Pearson 2 test or Fisher exact test. The probability value was considered to be significant at Ͻ0.05.
Univariable Cox proportional hazard analysis was performed to determine the relationship between clinical, stress ECG, echocardiographic variables, and cardiac events. Variables that reached statistical significance and were predictive of cardiac events in the univariable analysis were considered in the multivariable Cox proportional hazards analysis. Cumulative survival rates as a function of time after SE were generated by means of Kaplan-Meier survival analysis and compared by means of the log-rank test. Because the end point of the study was a composite of hard cardiovascular events (nonfatal MI and cardiac death), patients who underwent revascularization during follow-up were not censored at the time of revascularization. Because revascularization could affect the results of the study, a sensitivity analysis, excluding patients who underwent revascularization within 60 days of the SE (nϭ11), was performed by a univariable Cox proportional hazard analysis to evaluate the consistency in the relationship between an abnormal SE and cardiac events.
A forward selection process (Wald-Cox proportional hazard model) was used to find the incremental prognostic value of SE over traditional clinical, stress ECG, and rest echocardiographic parameters. Selection of variables for entry criteria were based on both univariable statistical significance and clinical judgment. The variables were entered in the order in which they were available to the physicians, with clinical variables entered first; followed by stress ECG, rest echocardiographic, and finally SE variables. A probability value of Ͻ0.05 was considered to be significant for entry, and Ͻ0.10 was required for retention in the model. A test of the proportional hazards assumption was performed by using a formal significance test, based on the Schoenfeld residuals. 20 The linearity assumption was also tested across the range of the continuous predictor variables. None of the variables violated the aforementioned assumptions.
Results
In the study cohort of 311 patients, 230 (74%) were men. There were 173 patients (56%) who underwent dobutamine SE and 138 patients (44%) who underwent exercise SE. Indications for SE were chest pain (61%), dyspnea (12%), cardiac risk factors (9%), evaluation of known CAD (6%), and other (12%).
Patient Characteristics
Among the 311 patients, 232 (74%) had a normal SE and 79 (26%) had an abnormal SE. Ischemia was present in 62 patients with an abnormal SE. Their demographics are characterized in Table 1 .
Among clinical characteristics, patients with an abnormal SE had a greater number of cardiovascular risk factors, such as hypertension, hyperlipidemia, known CAD, and prior MI, and were more likely to have typical angina. There were no significant differences in HIV-related variables such as mean duration of HIV infection, viral load, and use of antiretroviral therapy between both groups. The CD4 counts were higher in patients with a normal SE. Among the stress ECG characteristics, patients with an abnormal SE had a higher resting heart rate and blood pressure. The proportion of positive stress ECG was higher in patients with an abnormal SE (10% versus 2%, Pϭ0.002). Among resting echocardiographic characteristics, patients with an abnormal SE had a significantly lower LV ejection fraction and greater LV dimensions. Among SE characteristics, patients with an abnormal SE were less likely to exercise than those with a normal SE, had a higher LV stress WMSI, a greater number of ischemic segments, and a greater extent and severity of ischemia compared with those with a normal SE. All the patients with a normal SE who had resting wall motion abnormalities had a monophasic response (stress LV WMSI of 1).
Observed Events
Patients were followed up for 2.9Ϯ1.9 years (range, 3.1 months to 9.4 years). Patients without events had a minimum follow-up time of 6 months (range, 6 months to 9.4 years). Among the 311 patients included in our study, 17 nonfatal MI and 14 cardiac deaths occurred. Twentyseven hard events occurred in the group of patients with abnormal SE, whereas only 4 hard events occurred in the group of patients with normal SE. Periprocedural MI did not occur. The event rate for the entire cohort was 3.4% per year. SE effectively risk-stratified patients into normal and abnormal groups. The event rate for patients with a normal SE was 0.6% per year, compared with those with an abnormal SE, who had an event rate of 11.8% per year. Univariable clinical predictors of cardiac events were older age, known CAD, prior MI, and history of typical angina. Among stress ECG variables, a higher resting heart rate and a positive stress ECG were significant univariable predictors of cardiovascular events. Among echocardiographic variables, LV ejection fraction, higher (worse) LV resting and stress WMSI, an abnormal SE, higher number of abnormal and ischemic segments, greater extent and severity of ischemia, and the presence of any ischemia on SE were significant univariable predictors of cardiovascular events. The use of antiretroviral therapy at the time of testing, especially the use of nucleoside reverse transcriptase inhibitors (NRTI) was associated with fewer cardiac events ( Table 2) .
After adjusting for age, history of MI, maximum severity, abnormal SE, and the presence of any ischemia on SE, both abnormal SE and the presence of any ischemia on SE were independent predictors of cardiac events ( Table 2 ).
An abnormal SE portends a poor outcome, but, more importantly, a normal SE in this high-risk group portends a benign prognosis (Figure 1 ). In a sensitivity analysis, after excluding patients who underwent early (Ͻ60 days) revascularization (nϭ11), there was consistency in both the magnitude and direction of the effect size such that SE effectively risk-stratified patients into a normal versus an abnormal group (HR, 21.7; 95% CI, 7.6 to 62.2; PϽ0.0001).
Incremental Prognostic Value
SE also provided incremental prognostic value over traditional clinical, stress ECG, and resting echocardiographic variables (Figure 2 ). The global 2 increased from 17.8 to 24.5 to 65 to 109 (PϽ0.05 for all the groups).
Discussion
In the present study, we assessed the prognostic value of SE among HIV-infected patients with known or suspected CAD. The results of our study show that SE effectively risk-stratifies patients with HIV into a low-risk category (normal SE) and high-risk category (abnormal SE). Patients with HIV and a normal SE have a benign prognosis, similar to that of non-HIV-infected subjects. 18 The results of the present study show that the presence of LV ischemia and scar identified by SE is an independent predictor of cardiovascular outcomes in HIV-infected patients referred for SE.
HIV and Cardiovascular Events
Patients with HIV have increased risk of premature CAD and cardiovascular events. 4, 8, 21 Traditional cardiovascular risk factors as well as demographic and behavioral risk factors (ie, socioeconomic status, depression, and cocaine use) have been implicated in the presentation and progression of CAD. [22] [23] [24] Abnormal levels of inflammatory markers and immune activation have also been linked to adverse cardiovascular events. 6 Our results are concordant with prior observations, showing a high proportion of CAD (12.8%) and higher event rate in patients with HIV compared with the general population (3.4% per year versus 1.9% per year). 18 Similarly, there was a high prevalence of cardiovascular risk factors in this cohort, such as hypertension (61%), tobacco use (54%), hyperlipidemia (38%), and diabetes (27%).
Patients in our cohort and specifically in the group with abnormal SE were less likely to perform exercise stress testing (44%). This may have been the result of the high LA indicates left atrium. Hazard ratios, 95% CI, and P values were generated using a Cox proportional hazard analysis. prevalence of cardiovascular risk factors and comorbidities in these patients.
Antiretroviral Therapy and Cardiovascular Events
The use of antiretroviral therapy is associated with an increased risk of cardiovascular events. NRTI, specifically abacavir and didanosine, are associated with an excess risk of MI. [25] [26] [27] In the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) and the SMART studies, patients receiving abacavir were 1.7 to 4.3 times more likely to have an MI, whereas patients receiving didanosine were 1.4 times more likely to have an MI. In our study, the use of antiretroviral therapy at the time of testing, specifically NRTI use, was associated with fewer cardiac events. After adjustment for traditional cardiovascular risk factors such as hypertension, diabetes, hyperlipidemia, and smoking, the association of NRTI use with fewer cardiac events persisted (HR, 0.37; 95% CI, 0.15 to 0.89; Pϭ0.026). This discrepancy could be related to a lower exposure to abacavir-based (26% versus 37%) and didanosine-based (5.4% versus 41%) therapy in our cohort, compared with those patients in the D:A:D study 26 or changes in antiretroviral agents during follow-up. The median CD4 count was higher in the group with a normal SE. A CD4 count Ͼ400 cells/mL correlates with improved outcomes. 28
SE and HIV Patients
To our knowledge, this is the first study evaluating the role of SE in patients with HIV. Previous studies have explored the diagnostic role of stress ECG testing without associated imaging in HIV patients. Duong et al 29 used exercise stress ECG to evaluate the prevalence of silent myocardial ischemia in 99 asymptomatic HIV patients who had been receiving HAART for Ն12 months and did not have known CAD. In their study, older age, presence of lipodystrophy, and increased cholesterol level were independent predictors of silent myocardial ischemia (11%) as defined by a positive stress ECG. In our study, a positive stress ECG was observed in a lower proportion of patients (4%), and, even though on univariable analysis it showed a significant predictive value, after adjustment for rest and stress echocardiographic variables there was no association with cardiac events.
Prognostic Value of SE in HIV Patients
Peak stress WMSI is a semiquantitative form of defining ischemia by SE and incorporates both the extent and severity of wall motion abnormalities at peak stress. Our study shows that by using this same parameter, SE can risk-stratify HIV patients. After multivariable analysis, the risk of having a nonfatal MI or cardiac death in patients with evidence of ischemia on SE was 3.4 times higher than for those patients without ischemia, whereas the presence of scar and ischemia defined by an abnormal SE was associated with a 28-fold increased risk of cardiovascular events. The risk of cardiac events in patients with an abnormal SE was consistently increased (16-to 17-fold), independent of the stress testing modality. Furthermore, SE was able to identify a group of patients (normal SE) with a risk of future cardiovascular events that was not different from the general population (event rate Ͻ1% per year) and in whom the use of more expensive and invasive testing or interventions can be avoided. Patients with an abnormal SE have poor outcomes and may benefit from aggressive medical therapy and possibly coronary revascularization, whereas patients with a normal SE have a benign prognosis and may benefit from risk factor modification and optimized medical therapy.
Incremental Value of SE
SE parameters significantly enhanced the cumulative predictive power for future cardiac events when added to clinical, stress electrocardiographic, and resting echocardiographic variables.
Study Limitations
As frequently occurs in studies with SE, wall motion analysis is subjective, which may limit our capacity to extrapolate these results to centers with less experience. The results of the SE, available to the referring physicians, might have influenced the clinical treatment of these patients, especially with regard to revascularization, because patients with an abnormal SE tend to proceed to angiography and revascularization, thereby decreasing the outcomes from an abnormal test. Because of the limited number of cardiac events, we combined patients undergoing exercise SE and dobutamine SE for the analysis. However, in clinical practice, both exercise SE and dobutamine SE are routinely used for risk stratification of patients with known or suspected CAD. Furthermore, the analysis of patients undergoing exercise SE separately from patients undergoing dobutamine SE showed the consistency of the prognostic value of an abnormal SE between both stress testing modalities. In light of the limited number of events and the potential for multiplicity, our results should be interpreted with caution. We did not have data on changes in medication including HAART therapy or the follow-up CD4 counts on these patients. However, it is likely that the HIV treatment was similar between the normal and abnormal SE patients.
Conclusions
In this cohort at increased risk for cardiovascular events, SE effectively risk-stratifies patients into a normal SE (low risk) and abnormal SE (high risk) groups. Patients with a normal SE have a benign prognosis, with an event rate comparable to the general population (Ͻ1% per year). However, patients with an abnormal SE have poor outcomes and may benefit from aggressive interventions. Furthermore, an abnormal SE provides incremental prognostic value over traditional clinical, stress ECG, and resting echocardiographic variables.
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